Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IVVD 
Invivyd Inc. (IVVD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: IVVD (3-star) is a STRONG-BUY. BUY since 14 days. Simulated Profits (42.98%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.67
1 Year Target Price $5.67
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 210.43% | Avg. Invested days 28 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 403.09M USD | Price to earnings Ratio - | 1Y Target Price 5.67 |
Price to earnings Ratio - | 1Y Target Price 5.67 | ||
Volume (30-day avg) 3 | Beta 0.57 | 52 Weeks Range 0.35 - 2.74 | Updated Date 10/14/2025 |
52 Weeks Range 0.35 - 2.74 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.92 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -238.33% | Operating Margin (TTM) -127.78% |
Management Effectiveness
Return on Assets (TTM) -53.25% | Return on Equity (TTM) -120.08% |
Valuation
Trailing PE - | Forward PE 6.97 | Enterprise Value 223500295 | Price to Sales(TTM) 8.72 |
Enterprise Value 223500295 | Price to Sales(TTM) 8.72 | ||
Enterprise Value to Revenue 4.84 | Enterprise Value to EBITDA 0.78 | Shares Outstanding 214409450 | Shares Floating 72175794 |
Shares Outstanding 214409450 | Shares Floating 72175794 | ||
Percent Insiders 19.2 | Percent Institutions 60.73 |
Upturn AI SWOT
Invivyd Inc.
Company Overview
History and Background
Invivyd Inc., formerly Adagio Therapeutics, is a biopharmaceutical company focused on developing and commercializing antibody-based therapies for infectious diseases. It was founded in 2020 and has shifted focus due to the decreased effectiveness of its initial COVID-19 treatment against new variants.
Core Business Areas
- Monoclonal Antibody Development: Invivyd focuses on discovering, developing, and commercializing monoclonal antibodies to treat and prevent serious infectious diseases, particularly those that have the potential to become pandemic.
- Next-Generation Antibody Discovery: Employing innovative technologies to identify and engineer potent antibodies with broad coverage against evolving viral threats.
Leadership and Structure
Invivyd's leadership team consists of experienced professionals in biopharmaceutical development and commercialization. The organizational structure is typical of a biotech company, with research, development, and commercial functions.
Top Products and Market Share
Key Offerings
- Vixivrevimab (INV2021): A monoclonal antibody targeting SARS-CoV-2. Development was discontinued due to emerging viral variants. No market share achieved. Competitors included Regeneron (REGN), Eli Lilly (LLY), and AstraZeneca (AZN), all developing or having developed COVID-19 antibody treatments.
- Pipeline Programs: Invivyd is currently focused on developing new therapies for future variants and other viral threats. Market share is currently 0 for unreleased products. Competitors would be similar to those listed above, plus companies focusing on broader antiviral platforms.
Market Dynamics
Industry Overview
The infectious disease therapeutics market is characterized by intense competition, rapid innovation, and evolving regulatory landscapes. The emergence of novel pathogens and drug resistance drives continuous demand for new treatments.
Positioning
Invivyd aims to be a leader in developing antibody-based therapies for emerging viral threats, focusing on next-generation antibodies and proactive development. They aim to be a fast follower, with improved treatments.
Total Addressable Market (TAM)
The TAM for infectious disease therapeutics is substantial and varies depending on the specific disease. It is estimated in the tens of billions of dollars globally. Invivyd's positioning targets a niche market of rapid response therapeutics against emerging viruses and improving the current treatments.
Upturn SWOT Analysis
Strengths
- Experienced leadership team
- Focus on next-generation antibody development
- Potential for rapid response to emerging viral threats
- Strong technology platform for antibody discovery
Weaknesses
- Reliance on a limited number of programs
- High risk and uncertainty associated with drug development
- Limited financial resources compared to larger pharmaceutical companies
- History of failing initial treatments due to viral evolution
Opportunities
- Growing demand for infectious disease therapeutics
- Potential for partnerships and collaborations
- Advancements in antibody engineering and delivery technologies
- Government funding and support for pandemic preparedness
Threats
- Rapid viral evolution and drug resistance
- Competition from larger pharmaceutical companies
- Regulatory hurdles and delays
- Clinical trial failures
Competitors and Market Share
Key Competitors
- REGN
- LLY
- AZN
Competitive Landscape
Invivyd faces significant competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. Invivyd's advantage lies in its focus on next-generation antibodies and rapid response capabilities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is negative, reflecting the setback with their initial COVID-19 treatment and the subsequent restructuring.
Future Projections: Future projections depend entirely on the success of their pipeline programs. Analyst estimates vary widely, reflecting the inherent uncertainty in drug development.
Recent Initiatives: Recent initiatives include the development of new antibody candidates and strategic partnerships to expand their research capabilities.
Summary
Invivyd is a high-risk, high-reward biopharmaceutical company with a focus on developing antibody-based therapies for infectious diseases. Its initial setback with its COVID-19 treatment highlights the challenges of this field. Success depends on the clinical trial outcomes of its new programs and securing adequate funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Invivyd Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Invivyd Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2021-08-06 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 99 | Website https://invivyd.com |
Full time employees 99 | Website https://invivyd.com | ||
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.